Mode
Text Size
Log in / Sign up

Robot-assisted mastectomy with immediate reconstruction reduces overall complication risk compared to conventional mastectomyRobot assisted surgery may lower complication risks in breast cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that robot-assisted mastectomy reduces overall complication risk while maintaining comparable margin rates.

This systematic review and meta-analysis evaluated the outcomes of robot-assisted mastectomy (RAM) with immediate breast reconstruction (IBR) compared to conventional mastectomy (CM). The analysis included 3,985 patients. The primary finding was that margin status was comparable between RAM and CM (OR: 1.04; 95% CI: 0.43 to 2.52; p = 0.93).

Regarding safety and secondary outcomes, the meta-analysis reported a significantly lower risk of overall complications with RAM (OR: 0.76; 95% CI: 0.63 to 0.92; p = 0.004). While there was a non-significant trend toward improved BREAST-Q scores with RAM, the study noted that surgery duration was significantly longer in the RAM group. Intraoperative blood loss was reported as lower for RAM, though specific effect sizes were not provided.

The authors note several limitations, including substantial heterogeneity (I>50%) and potential selection bias. Additionally, there is a lack of long-term oncologic data to support long-term outcomes. These findings suggest that RAM with IBR may be a feasible alternative to CM for selected patients, though the evidence is tempered by these methodological constraints.

How this fits prior evidence

This meta-analysis addresses a gap in surgical techniques for breast cancer management. While previous coverage focused on pre-operative localization (magnetic seeds), systemic treatments (ICIs), and risk factors like PFOA exposure, this study provides data on the surgical approach of robot-assisted mastectomy. It confirms that RAM is a feasible alternative to conventional mastectomy by showing comparable margin status and reduced overall complications.

When a patient faces a mastectomy, the goal is twofold: removing the cancer while preparing the body for reconstruction. For many, choosing between traditional surgery and robot-assisted methods involves weighing the trade-offs in safety and recovery. A review of data from nearly 4,000 patients shows that using a robot during these procedures can significantly lower the risk of overall complications compared to conventional methods.

While the robot approach is associated with fewer complications and less blood loss during the operation, it does come with some trade-offs. Patients undergoing robot-assisted surgery often spend more time in the operating room and may have longer hospital stays. However, the results for margin status—the area of tissue left at the edge of the tumor—were comparable between both methods.

It is important to note that these findings come from a meta-analysis, which combines several studies. Because of differences in how those original studies were conducted, some uncertainty remains regarding long-term outcomes. Doctors can still use this information to help patients decide if a robot-assisted approach is a feasible and safe alternative for their specific needs.

What this means for you:
Robot-assisted mastectomy shows lower complication rates but involves longer surgery times and hospital stays.

Common questions

Is robot-assisted surgery safer than traditional surgery?

The data shows that robot-assisted mastectomy results in a significantly lower risk of overall complications compared to conventional methods. However, the surgical procedure takes longer and may lead to a longer stay in the hospital.

Does the robot change the success of removing the cancer?

No, the study found that margin status—the area at the edge of the tumor—was comparable between those who had robot-assisted surgery and those who had conventional surgery.

Are there any other differences in recovery or blood loss?

Patients who underwent robot-assisted procedures experienced less intraoperative blood loss. While there was a trend toward better quality of life scores, the results were not statistically significant.

Study Details

Study typeMeta analysis
Sample sizen = 3,985
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Robot-assisted mastectomy (RAM) is increasingly adopted in breast and plastic surgery with proposed benefits including improved cosmetic outcomes, surgical precision, and surgeon ergonomics. However, concerns remain regarding longer operative times. This systematic review and meta-analysis aimed to evaluate outcomes of RAM with immediate breast reconstruction (IBR) of any type compared with conventional mastectomy (CM). METHODS: The study was conducted according to PRISMA guidelines. Database searches were conducted (May 1, 2025) to identify studies assessing RAM with IBR. Studies were included if they reported at least 25 RAM procedures and at least one predefined outcome. Two meta-analyses were performed: A) a comparative meta-analysis including both RAM and CM cohorts, and B) a single-arm meta-analysis with RAM studies without a control group. Primary effect measures included odds ratios (ORs) and mean difference (MD). MAIN FINDINGS: Thirty studies comprising 3985 patients were included. Margin status was comparable between RAM and CM (OR: 1.04, 95% CI: 0.43 to 2.52, p = 0.93). RAM was associated with a significantly lower risk of overall complications (OR: 0.76, 95% CI: 0.63 to 0.92, p = 0.004), reduced intraoperative blood loss, and longer hospital stay. A non-significant trend towards improved BREAST-Q scores and reduced risk of individual complications was observed with RAM. Surgery duration was significantly longer in the RAM group, with an estimated learning curve of 17 procedures required to achieve a significant reduction in operative time. Substantial heterogeneity was observed across studies (I>50%). CONCLUSION: Current evidence suggests that RAM with IBR is a feasible alternative to CM in selected patients, with comparable margin status and similar overall complication rates. However, the evidence is limited by heterogeneity, potential selection bias, and lack of long-term oncologic data.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.